

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006



ORGANON

## Mometasone Suspension Formulation

Version 2.15      Revision Date: 09.04.2021      SDS Number: 23596-00018      Date of last issue: 16.10.2020  
Date of first issue: 21.10.2014

---

### SECTION 1: Identification of the substance/mixture and of the company/undertaking

#### 1.1 Product identifier

Trade name : Mometasone Suspension Formulation

#### 1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-stance/Mixture : Pharmaceutical

#### 1.3 Details of the supplier of the safety data sheet

Company : Organon & Co.  
Shotton Lane  
NE23 3JU Cramlington NU - Great Britain

Telephone : 44 1 670 59 30 00

E-mail address of person responsible for the SDS : EHSSTEWARD@organon.com

#### 1.4 Emergency telephone number

215-631-6999

---

### SECTION 2: Hazards identification

#### 2.1 Classification of the substance or mixture

##### Classification (REGULATION (EC) No 1272/2008)

Long-term (chronic) aquatic hazard, Category 2      H411: Toxic to aquatic life with long lasting effects.

#### 2.2 Label elements

##### Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms :



Hazard statements : H411 Toxic to aquatic life with long lasting effects.

Precautionary statements : **Prevention:**

P273 Avoid release to the environment.

**Response:**

P391 Collect spillage.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006



ORGANON

## Mometasone Suspension Formulation

Version 2.15      Revision Date: 09.04.2021      SDS Number: 23596-00018      Date of last issue: 16.10.2020  
Date of first issue: 21.10.2014

### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

## SECTION 3: Composition/information on ingredients

### 3.2 Mixtures

#### Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Mometasone	83919-23-7	Repr. 1B; H360Df STOT RE 2; H373 (Immune system, Liver, Kidney, Skin) Aquatic Chronic 1; H410  M-Factor (Chronic aquatic toxicity): 100	$\geq 0.025 - < 0.1$
Benzalkonium chloride	8001-54-5	Acute Tox. 3; H301 Acute Tox. 2; H330 Acute Tox. 3; H311 Skin Corr. 1; H314 Eye Dam. 1; H318 Aquatic Acute 1; H400 Aquatic Chronic 2; H411  M-Factor (Acute aquatic toxicity): 100	$\geq 0.0025 - < 0.025$

For explanation of abbreviations see section 16.

## SECTION 4: First aid measures

### 4.1 Description of first aid measures

- Protection of first-aiders : No special precautions are necessary for first aid responders.
- If inhaled : If inhaled, remove to fresh air.  
Get medical attention if symptoms occur.
- In case of skin contact : Wash with water and soap as a precaution.  
Get medical attention if symptoms occur.
- In case of eye contact : Flush eyes with water as a precaution.  
Get medical attention if irritation develops and persists.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006



ORGANON

## Mometasone Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 16.10.2020
2.15	09.04.2021	23596-00018	Date of first issue: 21.10.2014

If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention if symptoms occur.  
Rinse mouth thoroughly with water.

### 4.2 Most important symptoms and effects, both acute and delayed

None known.

### 4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

## SECTION 5: Firefighting measures

### 5.1 Extinguishing media

Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical

Unsuitable extinguishing media : None known.

### 5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides

### 5.3 Advice for firefighters

Special protective equipment for firefighters : Wear self-contained breathing apparatus for firefighting if necessary. Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

## SECTION 6: Accidental release measures

### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

### 6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Prevent spreading over a wide area (e.g. by containment or oil

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006



ORGANON

## Mometasone Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 16.10.2020
2.15	09.04.2021	23596-00018	Date of first issue: 21.10.2014

---

barriers).  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

### 6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Soak up with inert absorbent material.  
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

---

## SECTION 7: Handling and storage

### 7.1 Precautions for safe handling

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.  
Local/Total ventilation : Use only with adequate ventilation.  
Advice on safe handling : Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Take care to prevent spills, waste and minimize release to the environment.  
Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

### 7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers : Keep in properly labelled containers. Store in accordance with the particular national regulations.  
Advice on common storage : Do not store with the following product types:  
Strong oxidizing agents

### 7.3 Specific end use(s)

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006



ORGANON

## Mometasone Suspension Formulation

Version 2.15      Revision Date: 09.04.2021      SDS Number: 23596-00018      Date of last issue: 16.10.2020  
Date of first issue: 21.10.2014

Specific use(s) : No data available

### SECTION 8: Exposure controls/personal protection

#### 8.1 Control parameters

##### Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Glycerine	56-81-5	TWA (Mist)	10 mg/m <sup>3</sup>	GB EH40
Further information: Where no specific short-term exposure limit is listed, a figure three times the long-term exposure limit should be used.				
Cellulose	9004-34-6	TWA (inhalable dust)	10 mg/m <sup>3</sup>	GB EH40
<p>Further information: For the purposes of these limits, respirable dust and inhalable dust are those fractions of airborne dust which will be collected when sampling is undertaken in accordance with the methods described in MDHS14/4 General methods for sampling and gravimetric analysis or respirable, thoracic and inhalable aerosols., The COSHH definition of a substance hazardous to health includes dust of any kind when present at a concentration in air equal to or greater than 10 mg.m<sup>-3</sup> 8-hour TWA of inhalable dust or 4 mg.m<sup>-3</sup> 8-hour TWA of respirable dust. This means that any dust will be subject to COSHH if people are exposed to dust above these levels. Some dusts have been assigned specific WELs and exposure to these must comply with the appropriate limits., Most industrial dusts contain particles of a wide range of sizes. The behaviour, deposition and fate of any particular particle after entry into the human respiratory system, and the body response that it elicits, depend on the nature and size of the particle. HSE distinguishes two size fractions for limit-setting purposes termed 'inhalable' and 'respirable'. Inhalable dust approximates to the fraction of airborne material that enters the nose and mouth during breathing and is therefore available for deposition in the respiratory tract. Respirable dust approximates to the fraction that penetrates to the gas exchange region of the lung. Fuller definitions and explanatory material are given in MDHS14/4., Where dusts contain components that have their own assigned WEL, all the relevant limits should be complied with.</p>				
		TWA (Respirable dust)	4 mg/m <sup>3</sup>	GB EH40
<p>Further information: For the purposes of these limits, respirable dust and inhalable dust are those fractions of airborne dust which will be collected when sampling is undertaken in accordance with the methods described in MDHS14/4 General methods for sampling and gravimetric analysis or respirable, thoracic and inhalable aerosols., The COSHH definition of a substance hazardous to health includes dust of any kind when present at a concentration in air equal to or greater than 10 mg.m<sup>-3</sup> 8-hour TWA of inhalable dust or 4 mg.m<sup>-3</sup> 8-hour TWA of respirable dust. This means that any dust will be subject to COSHH if people are exposed to dust above these levels. Some dusts have been assigned specific WELs and exposure to these must comply with the appropriate limits., Most industrial dusts contain particles of a wide range of sizes. The behaviour, deposition and fate of any particular particle after entry into the human respiratory system, and the body response that it elicits, depend on the nature and size of the particle. HSE distinguishes two size fractions for limit-setting purposes termed 'inhalable' and 'respirable'. Inhalable</p>				

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006



ORGANON

## Mometasone Suspension Formulation

Version 2.15      Revision Date: 09.04.2021      SDS Number: 23596-00018      Date of last issue: 16.10.2020  
Date of first issue: 21.10.2014

	ble dust approximates to the fraction of airborne material that enters the nose and mouth during breathing and is therefore available for deposition in the respiratory tract. Respirable dust approximates to the fraction that penetrates to the gas exchange region of the lung. Fuller definitions and explanatory material are given in MDHS14/4., Where dusts contain components that have their own assigned WEL, all the relevant limits should be complied with.			
		STEL (inhalable dust)	20 mg/m <sup>3</sup>	GB EH40
	Further information: For the purposes of these limits, respirable dust and inhalable dust are those fractions of airborne dust which will be collected when sampling is undertaken in accordance with the methods described in MDHS14/4 General methods for sampling and gravimetric analysis or respirable, thoracic and inhalable aerosols., The COSHH definition of a substance hazardous to health includes dust of any kind when present at a concentration in air equal to or greater than 10 mg.m <sup>-3</sup> 8-hour TWA of inhalable dust or 4 mg.m <sup>-3</sup> 8-hour TWA of respirable dust. This means that any dust will be subject to COSHH if people are exposed to dust above these levels. Some dusts have been assigned specific WELs and exposure to these must comply with the appropriate limits., Most industrial dusts contain particles of a wide range of sizes. The behaviour, deposition and fate of any particular particle after entry into the human respiratory system, and the body response that it elicits, depend on the nature and size of the particle. HSE distinguishes two size fractions for limit-setting purposes termed 'inhalable' and 'respirable'. Inhalable dust approximates to the fraction of airborne material that enters the nose and mouth during breathing and is therefore available for deposition in the respiratory tract. Respirable dust approximates to the fraction that penetrates to the gas exchange region of the lung. Fuller definitions and explanatory material are given in MDHS14/4., Where dusts contain components that have their own assigned WEL, all the relevant limits should be complied with.			
Mometasone	83919-23-7	TWA	1 µg/m <sup>3</sup> (OEB 4)	Internal
	Further information: Skin			
		Wipe limit	10 µg/100 cm <sup>2</sup>	Internal

### Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

Substance name	End Use	Exposure routes	Potential health effects	Value
Glycerine	Workers	Inhalation	Long-term local effects	56 mg/m <sup>3</sup>
	Consumers	Ingestion	Long-term systemic effects	229 mg/kg bw/day
	Consumers	Inhalation	Long-term local effects	33 mg/m <sup>3</sup>

### Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

Substance name	Environmental Compartment	Value
Glycerine	Fresh water	0.885 mg/l
	Marine water	0.0885 mg/l
	Intermittent use/release	8.85 mg/l
	Sewage treatment plant	1000 mg/l
	Fresh water sediment	3.3 mg/kg dry weight (d.w.)
	Marine sediment	0.33 mg/kg dry weight (d.w.)

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006



ORGANON

## Mometasone Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 16.10.2020
2.15	09.04.2021	23596-00018	Date of first issue: 21.10.2014

	Soil	0.141 mg/kg dry weight (d.w.)
--	------	-------------------------------

### 8.2 Exposure controls

#### Engineering measures

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Essentially no open handling permitted.

Use closed processing systems or containment technologies.

If handled in a laboratory, use a properly designed biosafety cabinet, fume hood, or other containment device if the potential exists for aerosolization. If this potential does not exist, handle over lined trays or benchtops.

#### Personal protective equipment

- Eye protection : Wear safety glasses with side shields or goggles.  
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.  
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
- Hand protection
- Material : Chemical-resistant gloves
- Remarks : Consider double gloving.
- Skin and body protection : Work uniform or laboratory coat.  
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.  
Use appropriate degowning techniques to remove potentially contaminated clothing.
- Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.  
Equipment should conform to BS EN 14387
- Filter type : Combined particulates and organic vapour type (A-P)

## SECTION 9: Physical and chemical properties

### 9.1 Information on basic physical and chemical properties

- Appearance : liquid
- Colour : white to off-white, opaque
- Odour : odourless
- Odour Threshold : No data available
- pH : 4.3 - 4.9
- Melting point/freezing point : No data available
- Initial boiling point and boiling range : No data available
- Flash point : No data available

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006



ORGANON

## Mometasone Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 16.10.2020
2.15	09.04.2021	23596-00018	Date of first issue: 21.10.2014

---

Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available
Relative density	:	No data available
Density	:	1 g/cm <sup>3</sup>
Solubility(ies)		
Water solubility	:	soluble
Partition coefficient: n-octanol/water	:	Not applicable
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.

### 9.2 Other information

Molecular weight	:	Not applicable
Particle size	:	Not applicable

---

## SECTION 10: Stability and reactivity

### 10.1 Reactivity

Not classified as a reactivity hazard.

### 10.2 Chemical stability

Stable under normal conditions.

### 10.3 Possibility of hazardous reactions

Hazardous reactions	:	Can react with strong oxidizing agents.
---------------------	---	---

### 10.4 Conditions to avoid



# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006



ORGANON

## Mometasone Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 16.10.2020
2.15	09.04.2021	23596-00018	Date of first issue: 21.10.2014

Conditions to avoid : None known.

### 10.5 Incompatible materials

Materials to avoid : Oxidizing agents

### 10.6 Hazardous decomposition products

No hazardous decomposition products are known.

## SECTION 11: Toxicological information

### 11.1 Information on toxicological effects

Information on likely routes of exposure : Inhalation  
Skin contact  
Ingestion  
Eye contact

#### Acute toxicity

Not classified based on available information.

#### Components:

##### **Mometasone:**

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg  
LD50 (Mouse): > 2,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 3.3 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
Remarks: No mortality observed at this dose.

LC50 (Mouse): > 3.2 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist

Acute toxicity (other routes of administration) : LD50 (Rat): 300 mg/kg  
Application Route: Subcutaneous  
Symptoms: Breathing difficulties

##### **Benzalkonium chloride:**

Acute oral toxicity : LD50 (Rat): 240 mg/kg

Acute inhalation toxicity : LC50 (Rat, male): > 0.05 - 0.5 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
Method: OECD Test Guideline 403  
Assessment: Corrosive to the respiratory tract.  
Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rat, female): 704 mg/kg

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006



ORGANON

## Mometasone Suspension Formulation

Version 2.15      Revision Date: 09.04.2021      SDS Number: 23596-00018      Date of last issue: 16.10.2020  
Date of first issue: 21.10.2014

---

### Skin corrosion/irritation

Not classified based on available information.

#### Components:

##### **Mometasone:**

Species : Rabbit  
Result : No skin irritation

##### **Benzalkonium chloride:**

Species : Human  
Result : Corrosive after 4 hours or less of exposure

### Serious eye damage/eye irritation

Not classified based on available information.

#### Components:

##### **Mometasone:**

Species : Rabbit  
Result : No eye irritation

##### **Benzalkonium chloride:**

Species : Rabbit  
Result : Irreversible effects on the eye

### Respiratory or skin sensitisation

#### **Skin sensitisation**

Not classified based on available information.

#### **Respiratory sensitisation**

Not classified based on available information.

#### Components:

##### **Mometasone:**

Test Type : Maximisation Test  
Exposure routes : Dermal  
Species : Guinea pig  
Assessment : Does not cause skin sensitisation.  
Result : negative  
Remarks : The results of a test on guinea pigs showed this substance to be a weak skin sensitiser.

##### **Benzalkonium chloride:**

Test Type : Human repeat insult patch test (HRIPT)  
Exposure routes : Skin contact  
Species : Humans  
Result : negative

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006



ORGANON

## Mometasone Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 16.10.2020
2.15	09.04.2021	23596-00018	Date of first issue: 21.10.2014

---

### Germ cell mutagenicity

Not classified based on available information.

### Components:

#### **Mometasone:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: Chromosomal aberration  
Test system: Chinese hamster lung cells  
Result: negative

Test Type: Chromosomal aberration  
Test system: Chinese hamster ovary cells  
Result: positive

Test Type: Mouse Lymphoma  
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test  
Species: Mouse  
Application Route: Oral  
Result: negative

Test Type: Chromosomal aberration  
Species: Rat  
Cell type: Bone marrow  
Result: negative

Test Type: unscheduled DNA synthesis assay  
Species: Rat  
Cell type: Liver cells  
Result: negative

Germ cell mutagenicity- Assessment : Weight of evidence does not support classification as a germ cell mutagen.

#### **Benzalkonium chloride:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Method: OECD Test Guideline 476  
Result: negative  
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro  
Method: OECD Test Guideline 473  
Result: negative  
Remarks: Based on data from similar materials

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006



ORGANON

## Mometasone Suspension Formulation

Version 2.15      Revision Date: 09.04.2021      SDS Number: 23596-00018      Date of last issue: 16.10.2020  
Date of first issue: 21.10.2014

---

Species: Mouse  
Application Route: Ingestion  
Method: OECD Test Guideline 474  
Result: negative  
Remarks: Based on data from similar materials

### **Carcinogenicity**

Not classified based on available information.

### **Components:**

#### **Mometasone:**

Species : Rat  
Application Route : Inhalation  
Exposure time : 2 Years  
Dose : 0.067 mg/kg body weight  
Result : negative

Species : Mouse  
Application Route : Inhalation  
Exposure time : 19 Months  
Dose : 0.160 mg/kg body weight  
Result : negative

#### **Benzalkonium chloride:**

Species : Rat  
Application Route : Ingestion  
Exposure time : 2 Years  
Method : OECD Test Guideline 453  
Result : negative  
Remarks : Based on data from similar materials

Species : Mouse  
Application Route : Skin contact  
Exposure time : 80 weeks  
Result : negative

Species : Rabbit  
Application Route : Skin contact  
Exposure time : 90 weeks  
Result : negative

### **Reproductive toxicity**

Not classified based on available information.

### **Components:**

#### **Mometasone:**

Effects on fertility : Test Type: Fertility  
Species: Rat  
Application Route: Subcutaneous  
Fertility: NOAEL: 0.015 mg/kg body weight  
Symptoms: Reduced embryonic survival, Reduced foetal

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006



## Mometasone Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 16.10.2020
2.15	09.04.2021	23596-00018	Date of first issue: 21.10.2014

---

weight  
Result: No effects on fertility, Effect on reproduction capacity

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Mouse  
Application Route: Subcutaneous  
Embryo-foetal toxicity: LOAEL: 0.06 mg/kg body weight  
Result: Embryotoxic effects., Teratogenicity and developmental toxicity

Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Dermal  
Embryo-foetal toxicity: LOAEL: 0.3 mg/kg body weight  
Result: Embryo-foetal toxicity

Test Type: Embryo-foetal development  
Species: Rabbit  
Application Route: Dermal  
Embryo-foetal toxicity: LOAEL: 0.15 mg/kg body weight  
Result: Embryo-foetal toxicity, Malformations were observed.

Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Subcutaneous  
Embryo-foetal toxicity: LOAEL: 0.15 mg/kg body weight  
Result: Effects on newborn

Test Type: Embryo-foetal development  
Species: Rabbit  
Application Route: Oral  
Embryo-foetal toxicity: LOAEL: 0.7 mg/kg body weight  
Result: Embryo-foetal toxicity, Malformations were observed.

Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments., Some evidence of adverse effects on sexual function and fertility, based on animal experiments.

**Benzalkonium chloride:**

Effects on fertility : Test Type: Two-generation reproduction toxicity study  
Species: Rat  
Application Route: Ingestion  
Method: OECD Test Guideline 416  
Result: negative  
Remarks: Based on data from similar materials

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Rabbit  
Application Route: Ingestion  
Method: OECD Test Guideline 414  
Result: negative  
Remarks: Based on data from similar materials

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006



ORGANON

## Mometasone Suspension Formulation

Version 2.15      Revision Date: 09.04.2021      SDS Number: 23596-00018      Date of last issue: 16.10.2020  
Date of first issue: 21.10.2014

---

### STOT - single exposure

Not classified based on available information.

#### Components:

##### **Mometasone:**

Remarks : Based on available data, the classification criteria are not met.

### STOT - repeated exposure

Not classified based on available information.

#### Components:

##### **Mometasone:**

Exposure routes : inhalation (dust/mist/fume)  
Target Organs : Immune system, Liver, Kidney, Skin  
Assessment : May cause damage to organs through prolonged or repeated exposure.

##### **Benzalkonium chloride:**

Assessment : No significant health effects observed in animals at concentrations of 100 mg/kg bw or less.

### Repeated dose toxicity

#### Components:

##### **Mometasone:**

Species : Rat  
NOAEL : 0.005 mg/kg  
LOAEL : 0.3 mg/kg  
Application Route : Oral  
Exposure time : 30 d  
Target Organs : Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species : Dog  
LOAEL : 0.5 mg/kg  
Application Route : Oral  
Exposure time : 30 d  
Target Organs : Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species : Rat  
NOAEL : 0.00013 mg/l  
Application Route : inhalation (dust/mist/fume)  
Exposure time : 90 d  
Target Organs : Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, Liver, thymus gland

Species : Dog  
NOAEL : 0.0005 mg/l  
Application Route : inhalation (dust/mist/fume)  
Exposure time : 90 d  
Target Organs : Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow,

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006



ORGANON

## Mometasone Suspension Formulation

Version 2.15      Revision Date: 09.04.2021      SDS Number: 23596-00018      Date of last issue: 16.10.2020  
Date of first issue: 21.10.2014

---

Kidney, thymus gland, Liver

### **Benzalkonium chloride:**

Species : Rat  
NOAEL :  $\geq 100$  mg/kg  
Application Route : Ingestion  
Exposure time : 12 Weeks

### **Aspiration toxicity**

Not classified based on available information.

### **Components:**

#### **Mometasone:**

Not applicable

### **Experience with human exposure**

### **Components:**

#### **Mometasone:**

Inhalation : Symptoms: allergic rhinitis, Headache, pharyngitis, upper respiratory tract infection, sinusitis, oral candidiasis, Back pain, musculoskeletal pain, immune system effects, indigestion  
Skin contact : Symptoms: Dermatitis, Itching

### **Further information**

### **Components:**

#### **Mometasone:**

Remarks : Dermal absorption possible

---

## SECTION 12: Ecological information

### 12.1 Toxicity

### **Components:**

#### **Mometasone:**

Toxicity to fish : LC50 (Menidia beryllina (Silverside)): 0.11 mg/l  
Exposure time: 96 h  
Remarks: No toxicity at the limit of solubility  
  
LC50 (Cyprinodon variegatus (sheepshead minnow)):  $> 5$  mg/l  
Exposure time: 7 d  
Remarks: No toxicity at the limit of solubility  
  
Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)):  $> 5$  mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202  
Remarks: No toxicity at the limit of solubility

---

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006



ORGANON

## Mometasone Suspension Formulation

Version 2.15      Revision Date: 09.04.2021      SDS Number: 23596-00018      Date of last issue: 16.10.2020  
Date of first issue: 21.10.2014

---

- EC50 (Americamysis): > 5 mg/l  
Exposure time: 96 h  
Method: US-EPA OPPTS 850.1035  
Remarks: No toxicity at the limit of solubility
- Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 3.2 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201  
Remarks: No toxicity at the limit of solubility
- Toxicity to microorganisms : EC50 : > 1,000 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209  
Remarks: No toxicity at the limit of solubility
- NOEC : 1,000 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209  
Remarks: No toxicity at the limit of solubility
- Toxicity to fish (Chronic toxicity) : NOEC: 0.00014 mg/l  
Exposure time: 32 d  
Species: Pimephales promelas (fathead minnow)  
Method: OECD Test Guideline 210
- Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC: 0.34 mg/l  
Exposure time: 21 d  
Species: Daphnia magna (Water flea)  
Method: OECD Test Guideline 211  
Remarks: No toxicity at the limit of solubility
- M-Factor (Chronic aquatic toxicity) : 100
- Benzalkonium chloride:**
- Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 0.28 mg/l  
Exposure time: 96 h
- Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 0.0056 mg/l  
Exposure time: 48 h
- Toxicity to algae/aquatic plants : ErC50 (Chlorella pyrenoidosa (aglae)): 0.09 mg/l  
Exposure time: 72 h
- M-Factor (Acute aquatic toxicity) : 100
- Toxicity to fish (Chronic toxicity) : NOEC: 0.032 mg/l  
Exposure time: 34 d  
Species: Pimephales promelas (fathead minnow)



# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006



ORGANON

## Mometasone Suspension Formulation

Version 2.15      Revision Date: 09.04.2021      SDS Number: 23596-00018      Date of last issue: 16.10.2020  
Date of first issue: 21.10.2014

---

### 12.2 Persistence and degradability

#### Components:

##### **Mometasone:**

Biodegradability : Result: Not readily biodegradable.  
Biodegradation: 50 %  
Exposure time: 28 d  
Method: OECD Test Guideline 314

Stability in water : Hydrolysis: 50 %(12 d)  
Method: OECD Test Guideline 111

##### **Benzalkonium chloride:**

Biodegradability : Result: Readily biodegradable.  
Method: OECD Test Guideline 301D  
Remarks: Based on data from similar materials

### 12.3 Bioaccumulative potential

#### Components:

##### **Mometasone:**

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)  
Bioconcentration factor (BCF): 107.1  
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 4.68

##### **Benzalkonium chloride:**

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)  
Bioconcentration factor (BCF): < 500  
Remarks: Based on data from similar materials

Partition coefficient: n-octanol/water : log Pow: 1.692  
Remarks: Calculation

### 12.4 Mobility in soil

#### Components:

##### **Mometasone:**

Distribution among environmental compartments : log Koc: 4.02

### 12.5 Results of PBT and vPvB assessment

#### Product:

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006



## Mometasone Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 16.10.2020
2.15	09.04.2021	23596-00018	Date of first issue: 21.10.2014

0.1% or higher.

### 12.6 Other adverse effects

#### Product:

Endocrine disrupting potential : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

## SECTION 13: Disposal considerations

### 13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

## SECTION 14: Transport information

### 14.1 UN number

ADN : UN 3082  
ADR : UN 3082  
RID : UN 3082  
IMDG : UN 3082  
IATA : UN 3082

### 14.2 UN proper shipping name

ADN : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.  
(Mometasone, Benzalkonium chloride)

ADR : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.  
(Mometasone, Benzalkonium chloride)

RID : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.  
(Mometasone, Benzalkonium chloride)

IMDG : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.  
(Mometasone, Benzalkonium chloride)

IATA : Environmentally hazardous substance, liquid, n.o.s.  
(Mometasone, Benzalkonium chloride)

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006



ORGANON

## Mometasone Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 16.10.2020
2.15	09.04.2021	23596-00018	Date of first issue: 21.10.2014

---

### 14.3 Transport hazard class(es)

<b>ADN</b>	:	9
<b>ADR</b>	:	9
<b>RID</b>	:	9
<b>IMDG</b>	:	9
<b>IATA</b>	:	9

### 14.4 Packing group

**ADN**  
Packing group : III  
Classification Code : M6  
Hazard Identification Number : 90  
Labels : 9

**ADR**  
Packing group : III  
Classification Code : M6  
Hazard Identification Number : 90  
Labels : 9  
Tunnel restriction code : (-)

**RID**  
Packing group : III  
Classification Code : M6  
Hazard Identification Number : 90  
Labels : 9

**IMDG**  
Packing group : III  
Labels : 9  
EmS Code : F-A, S-F

**IATA (Cargo)**  
Packing instruction (cargo aircraft) : 964  
Packing instruction (LQ) : Y964  
Packing group : III  
Labels : Miscellaneous

**IATA (Passenger)**  
Packing instruction (passenger aircraft) : 964  
Packing instruction (LQ) : Y964  
Packing group : III  
Labels : Miscellaneous

### 14.5 Environmental hazards

**ADN**  
Environmentally hazardous : yes

**ADR**  
Environmentally hazardous : yes

**RID**

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006



ORGANON

## Mometasone Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 16.10.2020
2.15	09.04.2021	23596-00018	Date of first issue: 21.10.2014

Environmentally hazardous : yes

### IMDG

Marine pollutant : yes

### IATA (Passenger)

Environmentally hazardous : yes

### IATA (Cargo)

Environmentally hazardous : yes

### 14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

### 14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks : Not applicable for product as supplied.

## SECTION 15: Regulatory information

### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII)	:	Conditions of restriction for the following entries should be considered: Number on list 3
REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59).	:	Not applicable
REACH - List of substances subject to authorisation (Annex XIV)	:	Not applicable
Regulation (EC) No 1005/2009 on substances that deplete the ozone layer	:	Not applicable
Regulation (EU) 2019/1021 on persistent organic pollutants (recast)	:	Not applicable
Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals	:	Not applicable

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.

E2	ENVIRONMENTAL HAZARDS	Quantity 1 200 t	Quantity 2 500 t
----	-----------------------	---------------------	---------------------

### The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

### 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

## SECTION 16: Other information

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006



ORGANON

## Mometasone Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 16.10.2020
2.15	09.04.2021	23596-00018	Date of first issue: 21.10.2014

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

### Full text of H-Statements

H301 : Toxic if swallowed.  
H311 : Toxic in contact with skin.  
H314 : Causes severe skin burns and eye damage.  
H318 : Causes serious eye damage.  
H330 : Fatal if inhaled.  
H360Df : May damage the unborn child. Suspected of damaging fertility.  
H373 : May cause damage to organs through prolonged or repeated exposure if inhaled.  
H400 : Very toxic to aquatic life.  
H410 : Very toxic to aquatic life with long lasting effects.  
H411 : Toxic to aquatic life with long lasting effects.

### Full text of other abbreviations

Acute Tox. : Acute toxicity  
Aquatic Acute : Short-term (acute) aquatic hazard  
Aquatic Chronic : Long-term (chronic) aquatic hazard  
Eye Dam. : Serious eye damage  
Repr. : Reproductive toxicity  
Skin Corr. : Skin corrosion  
STOT RE : Specific target organ toxicity - repeated exposure  
GB EH40 : UK. EH40 WEL - Workplace Exposure Limits  
GB EH40 / TWA : Long-term exposure limit (8-hour TWA reference period)  
GB EH40 / STEL : Short-term exposure limit (15-minute reference period)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic sub-

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006



ORGANON

## Mometasone Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 16.10.2020
2.15	09.04.2021	23596-00018	Date of first issue: 21.10.2014

---

stance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

### Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

### Classification of the mixture:

Aquatic Chronic 2                      H411

### Classification procedure:

Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

GB / EN